TAIPEI, Taiwan – Founded in 2007, Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients with rare neurodegenerative diseases The company’s most anticipated product, Stemchymal®, an allogeneic adipose-derived mesenchymal stem cell (MSC) therapy, has completed Phase 2 clinical trials in Taiwan and Japan for spinocerebellar...
Latest News
Each year, about 20,000 children are diagnosed with Duchenne muscular dystrophy, a rare genetic condition that causes progressive muscle weakness and other systemic damage. Duchenne primarily affects males and is usually diagnosed by age 4. While a variety of therapies can slow progression and extend life expectancy, the disease has...
DOYLESTOWN, Pa. — Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients with Cushing’s Syndrome, a rare endocrine disorder with very limited available therapeutic options. An Investigators Meeting to start this...
STETSON, Maine — On a back road in the rural town of Stetson, a bright fuchsia and green RV is hard to miss, standing out against Maine’s bleak November scenery. Printed on the side of this van are a few inspirational quotes, and in larger letters are the words “Whitney...
BEDFORD, Mass. – Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, announced that it has completed a $40 million Series A financing to support the further advancement of multiple pre-clinical development programs. The Series A round...
BEDFORD, Mass. – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate...
BEDFORD, Mass. – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando,...
Football, faith and family play very important roles in the life of Davidson College linebacker Storm Monroe. Storm was just 9 years old in 2010 when he was diagnosed with Guillain-Barre syndrome. GBS is a rare disorder in which the body’s immune system attacks the nerves, usually resulting in weakness...
HORSHAM, Pa. — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces a groundbreaking clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat...
New Brunswick, NJ – Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer. “This work should help doctors know which patients’ prostate cancers will and won’t respond to the androgen deprivation therapy...